{"id":552438,"date":"2025-11-05T08:44:22","date_gmt":"2025-11-05T08:44:22","guid":{"rendered":"https:\/\/www.europesays.com\/de\/552438\/"},"modified":"2025-11-05T08:44:22","modified_gmt":"2025-11-05T08:44:22","slug":"tinnitus-uk-rates-lenire-as-most-effective-treatment-option","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/de\/552438\/","title":{"rendered":"Tinnitus UK Rates Lenire as Most Effective Treatment Option"},"content":{"rendered":"<ul type=\"disc\">\n<li>Lenire is now Tinnitus UK&#8217;s safest and most effective available tinnitus treatment option following a wholesale review of the charity&#8217;s rating system.<\/li>\n<li>Tinnitus UK&#8217;s new rating acknowledges Lenire&#8217;s large-scale clinical trials involving 600+ people and the device&#8217;s effectiveness in the real world.1,2,3<\/li>\n<li>Neuromod&#8217;s research for Lenire stands up to serious scrutiny per Tinnitus UK CEO, Alex Brooks-Johnson.<\/li>\n<\/ul>\n<p>DUBLIN, Nov. 5, 2025 \/PRNewswire\/ &#8212; <b>Tinnitus UK<\/b>, Europe&#8217;s leading tinnitus advocacy body, has announced that <b>Lenire<\/b> by <b>Neuromod<\/b> is now the highest rated available tinnitus treatment option for safety and effectiveness as part of the charity&#8217;s treatment rating review.<\/p>\n<p><img decoding=\"async\" id=\"prnejpg087bleft\" title=\"Tinnitus UK CEO, Alex Brooks-Johnson\" src=\"https:\/\/www.europesays.com\/de\/wp-content\/uploads\/2025\/11\/Tinnitus_UK_CEO.jpg\" alt=\"Tinnitus UK CEO, Alex Brooks-Johnson\" align=\"middle\"\/><\/p>\n<p>Lenire is now considered to be very safe, with a level of efficacy currently matched only by professional cognitive behavioural therapy (CBT) and hearing aids.<\/p>\n<p>&#8222;Neuromod welcomes Tinnitus UK&#8217;s decision to recognise Lenire, and bimodal neuromodulation, as a safe and effective standard of care for tinnitus treatment,&#8220; said Neuromod founding CEO, Dr. Ross O&#8217;Neill. &#8222;Millions of people in the UK and across Europe rely on Tinnitus UK for advice about treatment options and we are delighted that Neurmod&#8217;s commitment to building compelling evidence is reflected in this new rating for Lenire.&#8220;<\/p>\n<p><b>Lenire&#8217;s Tinnitus UK Reputation Built on Years of Research<\/b><\/p>\n<p>Lenire\u00ae is a bimodal neuromodulation device which has been proven to provide long lasting relief from tinnitus. Lenire treats tinnitus through a combination of auditory and tongue stimulation that retrains the brain to significantly reduce tinnitus focus.<\/p>\n<p>The device has been proven safe and effective with real world patients and across three large-scale clinical trials featuring more than 600 patients.1,2,3 Tinnitus UK&#8217;s rating acknowledges Lenire&#8217;s body of evidence according to Tinnitus UK CEO, Alex-Brooks Johnson.<\/p>\n<p>&#8222;Tinnitus UK&#8217;s vision is for a world without tinnitus, so new, rigorous research is welcomed with open arms. This change to the charity&#8217;s assessment of Lenire recognises years of hard work, building an evidence base that stands up to serious scrutiny.&#8220; said Tinnitus UK CEO, Alex Brooks-Johnson. &#8222;We hope it encourages other researchers and companies to do the same &#8211; to take tinnitus seriously, and give people living with tinnitus the treatment options that they need and deserve.&#8220;<\/p>\n<p><b>Lenire is Proven in Clinical Trials and with Real World Patients<\/b><\/p>\n<p>Lenire&#8217;s most recent clinical trial, TENT-A3, was a controlled clinical trial that was published in Nature Communications. TENT-A3 found Lenire was clinically superior to sound-only, the trial&#8217;s control, for the majority of patients with bothersome tinnitus.3<\/p>\n<p>Results from Lenire&#8217;s second large-scale clinical trial, TENT-A2, were published in Nature &#8211; Scientific Reports. TENT-A2 showed 95% of treatment compliant patients reported tinnitus improvement.2 91% reported long-term relief that sustained for at least a year after treatment ended.2<\/p>\n<p>Analysis of 220 real world Lenire patients further validated Lenire&#8217;s effectiveness as a tinnitus treatment device. The analysis, peer-reviewed and published in Nature Communications Medicine, showed that 91.5% of patients treated with Lenire had a clinically significant reduction in tinnitus after 12-weeks of treatment with Lenire.4<\/p>\n<p>&#8222;It&#8217;s fantastic to have Lenire as a tinnitus relief offering in our clinic, even more so now that it has been recognised by Tinnitus UK,&#8220; said owner of Byrom Audiology and Tinnitus UK Advisory Board Member, Peter Byrom. &#8222;It stands on years of rigorous research and we have seen life-changing results with our clients.&#8220;<\/p>\n<p><b>Lenire is Available Across the UK, US, and Europe<\/b><\/p>\n<p>Lenire is exclusively available through hearing healthcare professionals across the United Kingdom, Europe, and the United States of America. Tinnitus patients who wish to be assessed for Lenire can find a specialised clinic at www.lenire.com\/find-a-clinic\/.<\/p>\n<p><b>About Neuromod<\/b><\/p>\n<p>Neuromod is a global medical technology company with offices in Ireland and the USA. The company specializes in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.<\/p>\n<p>Neuromod has completed extensive clinical trials to confirm the safety and effectiveness of its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire. <\/p>\n<p>For more information about Neuromod visit <b>www.neuromod.com<\/b>.<\/p>\n<p><b>About Tinnitus UK<\/b><\/p>\n<p>Tinnitus UK, an independent charity dedicated to providing information and support for individuals living with tinnitus in the United Kingdom, plays a crucial role in enhancing the quality of life for those affected by this condition.<\/p>\n<p>The charity strives to facilitate improved well-being through a variety of support avenues, including online and in-person support groups, a helpline featuring a chatbot and live webchat, and an informative website.<\/p>\n<p>Tinnitus UK, receives no direct government funding and is committed to educating both medical professionals and the wider community about tinnitus, advocating prevention, and working towards finding a cure.<\/p>\n<p><b>About Tinnitus<\/b> <\/p>\n<p>Tinnitus is commonly known as &#8218;ringing in the ears&#8216;. It is a complex neurological condition that causes a perception of sound when there is no external source. It is estimated that 15% of the global adult population is living with tinnitus.5<\/p>\n<p><b>References<\/b><\/p>\n<ol type=\"1\">\n<li>Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020) <\/li>\n<li>Conlon et al., Nature Communications (2022), https:\/\/doi.org\/10.1038\/s41598-022-13875-x <\/li>\n<li>Boedts, M., Beuchner, A., Khoo, S.G. et al, Nature Communications (2024), https:\/\/doi.org\/10.1038\/s41467-024-50473-z. <\/li>\n<li>Mc Mahan, E., and Lim, H., Commun Med (2025), DOI: 10.1038\/s43856-025-00837-3<\/li>\n<li>R. Biswas et al., The Lancet Regional Health (2021), DOI:10.1016\/j.lanepe.2021.100250 <\/li>\n<\/ol>\n<p>Photo &#8211; https:\/\/www.europesays.com\/de\/wp-content\/uploads\/2025\/11\/Tinnitus_UK_CEO.jpg<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/www.europesays.com\/de\/wp-content\/uploads\/2025\/11\/1762332261_518_favicon.png\"\/> View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/tinnitus-uk-rates-lenire-as-most-effective-treatment-option-302604393.html<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=EN15194&amp;Transmission_Id=202511050030PR_NEWS_EURO_ND__EN15194&amp;DateId=20251105\" style=\"border:0px; width:1px; height:1px;\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"Lenire is now Tinnitus UK&#8217;s safest and most effective available tinnitus treatment option following a wholesale review of&hellip;\n","protected":false},"author":2,"featured_media":4508,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3976],"tags":[331,332,134164,134168,13,134167,67778,14,134163,15,34035,134166,12,134165,4339,3992,3993,3994,3995,3996,3997],"class_list":{"0":"post-552438","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-vereinigtes-koenigreich","8":"tag-aktuelle-nachrichten","9":"tag-aktuelle-news","10":"tag-devices","11":"tag-effective","12":"tag-headlines","13":"tag-lenire","14":"tag-most","15":"tag-nachrichten","16":"tag-neuromod","17":"tag-news","18":"tag-option","19":"tag-rates","20":"tag-schlagzeilen","21":"tag-tinnitus","22":"tag-treatment","23":"tag-uk","24":"tag-united-kingdom","25":"tag-united-kingdom-of-great-britain-and-northern-ireland","26":"tag-vereinigtes-koenigreich","27":"tag-vereinigtes-koenigreich-grossbritannien-und-nordirland","28":"tag-vereinigtes-koenigreich-von-grossbritannien-und-nordirland"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@de\/115496214611951547","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/552438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/comments?post=552438"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/552438\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media\/4508"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media?parent=552438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/categories?post=552438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/tags?post=552438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}